Assessment of Endometrial Thickness Among Adolescent and Young Adult Patients on Estrogen Replacement Therapy Using Daily Oral Micronized Progesterone Versus the Etonogestrel Implant.

NCT06357442

Status	RECRUITING
Sponsor	University of Colorado, Denver
Enrollment	34 participants

Key Eligibility Criteria

Inclusion (6)

- Age 12-25 years at baseline
- Female assigned at birth, with uterus
- Diagnosis of primary ovarian insufficiency or hypogonadotropic hypogonadism, requiring estrogen replacement therapy
- Receiving estradiol therapy-oral (1-2mg) or transdermal (0.05-0.1mg)-for at least 3 months
- Never used progesterone therapy or discontinued progesterone therapy at least 90-days prior to enrollment

... and 1 more (see full listing online)

Exclusion (4)

- Uterine abnormality (e.g., Müllerian Anomaly, uterine fibroids)
- Inability to characterize the endometrial lining on ultrasound
- History of chemotherapy or radiation therapy
- Inability to complete study questionnaire

Locations (1 total)

Childrens Hospital Colorado, Aurora, Colorado, United States